Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92426 citas

 
 
 1 a 20 de 255 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: A retrospective cohort study. Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102649]
2. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
3. Cita con resumen
Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415. [Ref.ID 101633]
4. Cita con resumen
Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn SO, Hüter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schädler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM, SepNet-Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316:1775-85. [Ref.ID 100934]
5. Cita con resumen
Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016;375:1638-48. [Ref.ID 100914]
6.Tiene citas relacionadas Cita con resumen
Timsit J-F, Azoulay E, Schwebel C, Charles P-E, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet J-L, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou J-C, Foucrier A, Allaouchiche B, Das V, Gangneux J-P, Ruckly S, Maubon D, Jullien V, Wolff M, for the EMPIRICUS Trial Group. Empirical micafungin treatment and survival whithout invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure. The EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-64. [Ref.ID 100904]
7.Tiene citas relacionadas
Siddharthan T, Karakousis PC, Checkley W. Empiral antifungal therapy in critically ill patients with sepsis. Another case of less is more in the ICU. JAMA 2016;316:1549-50. [Ref.ID 100903]
8.Enlace a cita original Cita con resumen
Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667-73. [Ref.ID 100766]
9. Cita con resumen
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, for the VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016;316:509-18. [Ref.ID 100687]
11.Enlace a cita original Cita con resumen
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016;353:i1585. [Ref.ID 100339]
13.
Seymour CW, Rosengart MR. Septic shock: advances in diagnosis and treatment. JAMA 2015;314:708-17. [Ref.ID 99498]
15. Cita con resumen
Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, D'Egidio A, Cecchini V, Landoni G, Pietrapaoli P, Westphal M, Venditti M, Mebazaa A, Singer M. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8. [Ref.ID 95957]
16.Tiene citas relacionadas Cita con resumen
Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:1212. [Ref.ID 95405]
17.Tiene citas relacionadas Cita con resumen
Prowle JR, Pearse RM. Is it the end of the road for synthetic starches in critical illness?. BMJ 2013;346:10. [Ref.ID 95404]
18.
Boyer A, Gruson D, Bouchet S, Clozeau B, Hoan-Nam B, Vargas F, Gilles H, Molimard M, Rogues A-M, Moore N. Aminoglycosides in septic shock - An overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013;36:217-30. [Ref.ID 95310]
19. Cita con resumen
Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugemier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang C-S, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent J-L, for the ACCESS Study Group. Effect of eritoran, an antagonist of MED2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62. [Ref.ID 95110]
20. Cita con resumen
Herzig SJ, Rothberg MB, Feinbloom DB, Howell MD, Ho KKL, Ngo LH, Marcantonio ER. Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients. J Gen Intern Med 2013;28:683-90. [Ref.ID 94625]
Seleccionar todas
 
 1 a 20 de 255 siguiente >>